Abstract: The present disclosure provides a preparation method of resveratrol nervonic acid ester, comprising the following steps of: step 1: weighing resveratrol, a nervonic acid and thiocarbonyldiimidazole according to a molar ratio of 1:1:0.8 to 1:7:11.2 in a reactor; step 2: adding a certain amount of solvent into the reactor to completely dissolve the reactants; and step 3: stirring for reaction at room temperature for 30 min to 180 min. The preparation method is safe, efficient and clean, and enables synthesis of the resveratrol nervonic acid ester with high conversion rate, high purity and high yield.

Abstract: This invention concerns a process for the production of vinyl esters of carboxylic acids with 3 to 20 carbon atoms, via vinylation in the presence of palladium (Pd) catalyst in combination with copper (Cu) as co-catalyst stabilized by organic salts in the presence of ethylene and air or oxygen.

Abstract: There is provided a compound having a structure represented by the following Formula (1), in Formula (1), R1 and R2 each independently represent a phenyl group having a substituent or an unsubstituted phenyl group, R3 and R4 each independently represent a C2-C12 alkyl group having a substituent or an unsubstituted C2-C12 alkyl group, a cyano group, a trifluoromethyl group, or a halogen atom, R5 and R6 each independently represent a hydrogen atom or an alkyl group, R7 represents a phenyl group having a substituent, an unsubstituted phenyl group, or a heteroaromatic group having a specific structure, and X? represents an anion, and in a case where at least one anionic substituent is included in a molecule, X? may not be present.

Abstract: The invention relates to psychoactive medicines including 2C-B, methylone, MBDB, their respective metabolites, isomers, enantiomers, polymorphs, and analogues (2C-series and cathinones); their preparation, formulations, intermediates, routes of administration, dosing and schedule for medical uses for psychiatric and neurological conditions and disorders.

Abstract: The present invention provides a novel method of initiating or escalating dofetilide dosage with the goal of maximizing patient safety while shortening the time period required for electrocardiographic monitoring from three days to one day.

Abstract: This disclosure relates to JAK1 pathway inhibitors and their use in treating vitiligo.

Abstract: The present invention relates to a process for the preparation of iloprost of formula I through new intermediates, isolation of iloprost of formula I in solid form, as well as preparation of the 16(S)-iloprost and 16(R)-iloprost isomers of formulae (S)-I and (R)-I and isolation of iloprost of formula I and 16(S)-iloprost of formula (S)-I in solid, crystalline form.

Abstract: The invention relates to a method for preparation of (meth)acrylic acid esters from (meth)acrylic acid anhydrides. Wherein the method for preparation of the (meth)acrylic acid ester, comprises at least step (a) as follows: (a) reacting a (meth)acrylic acid anhydride of Formula (I): wherein R1 is a hydrogen atom or a methyl group; with a substrate in the presence of a first catalyst to form a product mixture comprising the (meth)acrylic acid ester; and wherein: the substrate is selected from the group consisting of: primary alcohols; secondary alcohols; tertiary alcohols; and phenols; and the first catalyst comprises a salt of magnesium or of a rare earth element.

Abstract: Disclosed in the present disclosure are a novel injection polyaminopolycarboxylic acid-modified abiraterone derivative for treatment of prostate tumor, a pharmaceutical preparation containing the polyaminopolycarboxylic acid-modified abiraterone derivative, a preparation method, and an application. The polyaminopolycarboxylic acid-modified abiraterone derivative has the following structure (I). The polyaminopolycarboxylic acid-modified abiraterone derivative in the present disclosure has good water solubility, can be completely dissolved in an aqueous solution of sodium bicarbonate, is simple and convenient to prepare, high in yield, and suitable for large-scale production, has a remarkable effect in resisting tumors, can be used for treating prostate cancer tumor, and has the characteristics of high efficiency and low toxicity.

Abstract: The invention relates to a method for producing a polycarbonate and the reaction of one or more diaryl carbonates with one or more aromatic compounds, wherein a catalyst combination is used in the process. The invention further relates to a catalyst combination and to the use thereof in a process for producing a polycarbonate.

Abstract: A process for producing alkyl methacrylates, in particular methyl methacrylate (MMA), includes production of methacrolein (MAL) in a first reaction stage; direct oxidative esterification (DOE) of the methacrolein with an alcohol, preferably methanol, to afford an alkyl methacrylate in a second reaction stage; and workup of the alkyl methacrylate crude product from the second reaction stage. An optimized workup of the reactor output from the oxidative esterification of methacrolein involves minimizing the amount of employed water, the amount of employed acid, and/or the amount of aqueous waste streams, through an optimized recycling of the generated process water streams.

Abstract: The present disclosure provides methods and processes for the recovery of compounds (e.g., pendant groups) from polymeric materials, as well as methods for recycling and reusing such compounds by synthetically converting a recovered compound to building blocks that can be used in, e.g., curable resins for the fabrication of new devices, such as medical devices (e.g., orthodontic appliances).

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: In the embodiments, an aqueous hydrochloric acid solution instead of hydrogen chloride gas and solid triphosgene instead of phosgene gas may be used in the process of preparing a diisocyanate from a diamine through a diamine hydrochloride. In addition, the embodiments provide processes for preparing a diisocyanate composition and an optical lens of higher quality by controlling the water content in the diamine hydrochloride composition for preparing a diisocyanate within a specific range.

Abstract: Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.

Abstract: The present invention relates to a method for preparing glufosinate or an analogue and an intermediate thereof. The method comprises: a) reacting a compound of formula (II), an alcohol of formula (III) and a compound of formula (V); and b) hydrolyzing the product of the reaction above to obtain glufosinate of formula (IV) or an analogue thereof.

Abstract: The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms thereof.

Abstract: Disclosed are novel multi-substituent psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a substituent containing compound.

Abstract: Disclosed is a JAK1 and/or JAK2 inhibitor of the following structural formula: or a pharmaceutically acceptable salt thereof. This invention also provides pharmaceutical compositions comprising a compound of Formula (I), optionally including additional therapeutic agents, and use in methods of treatment for hair loss disorders.

Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, status epilepticus.